Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Market Cap	29.58M
Revenue (ttm)	n/a
Net Income (ttm)	-3.15M
Shares Out	45.51M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,000
Average Volume	19,405
Open	0.6700
Previous Close	0.6200
Day's Range	0.6200 - 0.6700
52-Week Range	0.5100 - 0.8000
Beta	0.79
RSI	54.74
Earnings Date	Apr 28, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company’s lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Patrice Rioux
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TTI